IC-MPGN Clinical Trial
— APPARENTOfficial title:
A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Iptacopan (LNP023) in Idiopathic Immune Complex Mediated Membranoproliferative Glomerulonephritis (IC-MPGN)
This study is designed as a multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the efficacy and safety of iptacopan (LNP023) in idiopathic immune complex mediated membranoproliferative glomerulonephritis.
Status | Recruiting |
Enrollment | 68 |
Est. completion date | November 26, 2026 |
Est. primary completion date | October 23, 2026 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 12 Years to 60 Years |
Eligibility | Inclusion Criteria: - Male and female participants age = 12 and = 60 years at screening. - Diagnosis of idiopathic IC-MPGN as confirmed by kidney biopsy within 12 months prior to screening in adults and within 3 years of screening in adolescents (a biopsy report, review and confirmation by the Investigator is required). If such a biopsy is not available in an adult participant, this must be obtained at screening (performed and assessed locally for adults only). - Prior to randomization, all participants must have been on a maximally recommended or tolerated dose of renin angiotensin system inhibitors (RASi), e.g an ACEi or ARB for at least 90 days (or as according to local guidelines). The doses of other drugs administered to reduce proteinuria and control the disease including mycophenolic acids (MPAs - mycophenolate mofetil or mycophenolate sodium), corticosteroids, SGLT2 inhibitors and mineralocorticoid receptor antagonists should be stable for at least 90 days prior to randomization - UPCR = 1.0 g/g (= 113 mg/mmol) sampled from the first morning void urine sample at Day -75 and Day -15 - Estimated GFR (using the chronic kidney disease [CKD]-EPI formula for adult participants and modified Schwartz formula for adolescents aged 12 to 17 years) or measured GFR = 30 ml/min/1.73m2 at screening and Day -15. - Mandatory vaccination against Neisseria meningitidis and Streptococcus pneumoniae infection prior to the start of study treatment. If the participant has not been previously vaccinated, or if a booster is required, the vaccine should be given according to local regulations at least 2 weeks prior to the first administration of study treatment. If the study treatment has to start earlier than 2 weeks post vaccination, prophylactic antibiotic treatment should be initiated in accordance with local standard of care. - If not previously vaccinated, or if a booster is required, vaccination against Haemophilus influenzae infections should be given, if available and according to local regulations, at least 2 weeks prior to the first study treatment administration. If the study treatment has to start earlier than 2 weeks post vaccination, prophylactic antibiotic treatment should be initiated in accordance with local standard of care. Exclusion Criteria: - Participants who have undergone cell or solid organ transplantation, including kidney transplantation. - Participants diagnosed with secondary IC-MPGN including but not limited to any of the following conditions: - Deposition of antigen-antibody immune complexes as a result of any chronic infections, including - Hepatitis C virus (HCV) including HCV-associated mixed cryoglobulinemia, hepatitis B virus (HBV); - Bacterial-endocarditis, infected ventriculo-atrial shunt, visceral abscesses, leprosy, meningococcal meningitis; chronic bacterial infections - Protozoa/other infections- malaria, schistosomiasis, mycoplasma, leishmaniasis, filariasis, histroplasmosis Renal deposition of immune complexes as a result of a systemic autoimmune disease: - Systemic lupus erythematosus (SLE) - Sjögren syndrome - Rheumatoid arthritis - Mixed connective tissue disease Deposition of monoclonal immunoglobulins because of a monoclonal gammopathy due to plasma cell or B cell disorders. Monoclonal gammopathy of undetermined significance (MGUS) confirmed by the measurement of serum free light chains or other investigation as per local standard of care. Fibrillary glomerulonephritis - Rapidly progressive crescentic glomerulonephritis defined as a 50% decline in the eGFR within 3 months with kidney biopsy findings of glomerular crescent formation seen in at least 50% of glomeruli on the most recent biopsy. - Kidney biopsy showing interstitial fibrosis/tubular atrophy (IF/TA) of more than 50%. - Participants with an active systemic bacterial, viral or fungal infection within 14 days prior to study treatment administration or the presence of fever = 38°C (100.4°F) within 7 days prior to study treatment administration. - A history of recurrent invasive infections caused by encapsulated organisms, e.g., Neisseria meningitidis and Streptococcus pneumoniae. - The use of inhibitors of complement factors (e.g., Factor B, Factor D, complement 3 (C3) inhibitors, anti-Complement 5 (C5) antibodies, C5a receptor antagonists) within 6 months prior to the Screening visit. - The use of immunosuppressants (except MPAs), cyclophosphamide or systemic corticosteroids at a dose >7.5 mg/day (or equivalent for a similar corticosteroid medication) within 90 days of study drug administration. - The use of MPAs is not permitted within 90 days prior to randomization in India, as per the local health authority requirement. - Acute post-infectious glomerulonephritis at screening, based upon the opinion of the investigator. - Body mass index (BMI) >38 kg/m2 at screening and randomization. Body weight <35 kg at screening and randomization |
Country | Name | City | State |
---|---|---|---|
Argentina | Novartis Investigative Site | Caba | Buenos Aires |
Brazil | Novartis Investigative Site | Belo Horizonte | MG |
Brazil | Novartis Investigative Site | Botucatu | SP |
Brazil | Novartis Investigative Site | Brasilia | DF |
Brazil | Novartis Investigative Site | Niteroi | RJ |
Brazil | Novartis Investigative Site | Pernambuco | Recife |
Brazil | Novartis Investigative Site | Porto Alegre | RS |
Brazil | Novartis Investigative Site | Rio de Janeiro | RJ |
Brazil | Novartis Investigative Site | Salvador | |
Brazil | Novartis Investigative Site | Santo Andre | SP |
Brazil | Novartis Investigative Site | Sao Paulo | SP |
Brazil | Novartis Investigative Site | São Paulo | SP |
Canada | Novartis Investigative Site | Montreal | Quebec |
Czechia | Novartis Investigative Site | Prague 2 | |
France | Novartis Investigative Site | Montpellier | |
France | Novartis Investigative Site | Paris | |
France | Novartis Investigative Site | Paris 15 | |
France | Novartis Investigative Site | Toulouse 4 | |
Germany | Novartis Investigative Site | Berlin | |
Germany | Novartis Investigative Site | Dresden | |
Germany | Novartis Investigative Site | Essen | |
Germany | Novartis Investigative Site | Mainz | |
India | Novartis Investigative Site | Nagpur | Maharashtra |
India | Novartis Investigative Site | New Delhi | |
Israel | Novartis Investigative Site | Haifa | |
Israel | Novartis Investigative Site | Jerusalem | |
Israel | Novartis Investigative Site | Petach Tikva | |
Italy | Novartis Investigative Site | Bari | BA |
Italy | Novartis Investigative Site | Milano | MI |
Italy | Novartis Investigative Site | Napoli | |
Italy | Novartis Investigative Site | Ranica | BG |
Italy | Novartis Investigative Site | Roma | RM |
Italy | Novartis Investigative Site | Torino | TO |
Japan | Novartis Investigative Site | Hachioji-city | Tokyo |
Japan | Novartis Investigative Site | Okayama-city | Okayama |
Poland | Novartis Investigative Site | Olsztyn | |
Poland | Novartis Investigative Site | Warszawa | |
Poland | Novartis Investigative Site | Warszawa | |
Poland | Novartis Investigative Site | Wroclaw | |
Spain | Novartis Investigative Site | Barcelona | Catalunya |
Spain | Novartis Investigative Site | Madrid | |
Spain | Novartis Investigative Site | Madrid | |
Spain | Novartis Investigative Site | Pamplona | Navarra |
Spain | Novartis Investigative Site | Salamanca | Castilla Y Leon |
Switzerland | Novartis Investigative Site | Bern | |
Switzerland | Novartis Investigative Site | Lausanne | |
Turkey | Novartis Investigative Site | Ankara | |
Turkey | Novartis Investigative Site | Izmir | |
Turkey | Novartis Investigative Site | Kocaeli | |
United Kingdom | Novartis Investigative Site | Belfast | |
United Kingdom | Novartis Investigative Site | Cardiff | |
United States | Childrens Hospital Colorado | Aurora | Colorado |
United States | Massachusetts General Hospital Nephrology Department | Boston | Massachusetts |
United States | Ronald Reagan UCLA Medical Center UCLA Connie Frank Clinic | Los Angeles | California |
United States | University of Minnesota Renal Disease and Hypertension | Minneapolis | Minnesota |
United States | Col Uni Med Center New York Presby | New York | New York |
United States | Univ Cali Irvine ALS Neuromuscular Tustin | Orange | California |
United States | UCSF Main Centre | San Francisco | California |
United States | Baylor Scott and White Research . | Temple | Texas |
Vietnam | Novartis Investigative Site | Ho Chi Minh |
Lead Sponsor | Collaborator |
---|---|
Novartis Pharmaceuticals |
United States, Vietnam, Argentina, Brazil, Canada, Czechia, France, Germany, India, Israel, Italy, Japan, Poland, Spain, Switzerland, Turkey, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Log-transformed ratio to baseline in UPCR (sampled from a 24-hour urine collection) at 6 months. | To demonstrate the superiority of iptacopan compared to placebo in reducing proteinuria at 6 months. | 6 months (double-blind) | |
Primary | Log-transformed ratio to baseline in UPCR at the 12-month visit (both study treatment arms) | To evaluate the effect of iptacopan on proteinuria at 12 months. | 12 months | |
Primary | Log-transformed ratio to 6-month visit in UPCR at the 12-month visit in the placebo arm. | To evaluate the effect of iptacopan on proteinuria at 12 months. | 12 months | |
Secondary | Change from baseline in eGFR | To demonstrate the superiority of iptacopan vs. placebo in improving estimated glomerular filtration rate (eGFR). | 6 months of double-blind & 6 months of open label (up to 12 months) | |
Secondary | Change in eGFR from the 6-month visit to the 12- month visit of the placebo arm | To evaluate the effect at 12 months of iptacopan in improving eGFR | month 6 and month 12 | |
Secondary | Proportion of patients achieved a composite renal endpoint | To demonstrate the superiority of iptacopan vs. placebo in the proportion of participant who achieved a composite renal endpoint at 6 and 12 months (both study arms). | 6 months of double-blind & 6 months of open label (up to 12 months) | |
Secondary | Proportion of patients achieving a composite renal endpoint from the 6-month visit to the 12-month visit of the placebo arm | To evaluate the effect at 12 months of iptacopan on a composite renal endpoint in placebo arm | month 6, month 12 | |
Secondary | Change from baseline in the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) score. | To demonstrate the superiority of iptacopan compared to placebo in improvement of patient-reported fatigue at 6 months and 12 months (both study arms). | 6 months of double-blind & 6 months of open label (up to 12 months) | |
Secondary | Change in the FACIT-Fatigue score from the 6-month visit to the 12-month visit at the placebo arm | To evaluate the effect at 12 months of iptacopan in improvement of participant-reported fatigue in placebo arm | month 6, month 12 | |
Secondary | Number of participants with abnormal vital signs, ECGs and safety laboratory measurements | To evaluate the safety and tolerability of iptacopan compared to placebo, number of participants with abnormal vital signs (msDBP/msSBP/heart rate), ECGs and safety laboratory measurements will be collected.
msDBP: mean sitting diastolic blood pressure msSBP: mean sitting systolic blood pressure |
6 months of double-blind & 6 months of open label (up to 12 months) | |
Secondary | Number of participants with study drug discontinuation due to an AE | To evaluate the safety and tolerability of iptacopan compared to placebo, number of participants with study drug discontinuation due to an AE (or any safety issue) will be collected | 6 months of double-blind & 6 months of open label (up to 12 months) | |
Secondary | Number of participants with clinically significant changes in heart rate, blood pressure, echocardiography parameters and NT-proBPN in adolescent patients | To evaluate the effect of iptacopan compared to placebo, number of participants with clinically significant changes in heart rate, blood pressure (msDBP/ msSBP), echocardiography parameters and NT-proBPN in adolescent patients will be collected | 6 months of double-blind & 6 months of open label (up to 12 months) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05067127 -
Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis
|
Phase 3 | |
Active, not recruiting |
NCT05809531 -
An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis
|
Phase 3 | |
Terminated |
NCT03459443 -
A Proof of Concept Study for a 12 Month Treatment in Patients With C3G or IC-MPGN Treated With ACH-0144471
|
Phase 2 | |
Active, not recruiting |
NCT04572854 -
Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN
|
Phase 2 | |
Completed |
NCT03723512 -
Non-contrast Enhanced MRI in Patients With C3 Glomerulopathy (C3G) or Immune-complex Membranoproliferative Glomerulonephritis (IC-MPGN) Enrolled in the ACH471-205 Study
|
N/A | |
Available |
NCT04729062 -
C3G/Primary IC-MPGN EAP
|